Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma

References

• Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51–88.
   PubMed Web of Science ®Google Scholar
• Lourenco GJ, Lorand-Metze I, Delamain MT, . Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma 2010;51:2215–2221.
   PubMed Web of Science ®Google Scholar
• Lourenco GJ, Neri IA, Sforni VC, . Polymorphisms of glutathione S-transferase mu 1, glutathione S-transferase theta 1 and glutathione S-transferase pi 1 genes in Hodgkin's lymphoma susceptibility and progression. Leuk Lymphoma 2009;50:1005–1009.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Massini G, D’Alo’ F, . Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res 2003;9:3435–3440.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Di Ruscio A, Di Febo A, . Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 2005;11:2175–2179.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Casasnovas O, . Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood 2009;113:3307–3313.
   PubMed Web of Science ®Google Scholar
• Soucek P, Sarmanova J, Kristensen VN, . Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Int Arch Occup Environ Health 2002;75(Suppl.):S86–S92.
   PubMed Web of Science ®Google Scholar
• Ekhart C, Rodenhuis S, Smits PH, . An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 2009;35:18–31.
   PubMed Web of Science ®Google Scholar
• Zimniak P, Nanduri B, Pikula S, . Naturally occurring human glutathione S-transferase GSTP1 - 1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994;224:893–899.
   PubMedGoogle Scholar
• Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003;22:7369–7375.
   PubMed Web of Science ®Google Scholar
• Grotmol T, Bray F, Holte H, . Frailty modeling of the bimodal age-incidence of Hodgkin lymphoma in the Nordic countries. Cancer Epidemiol Biomarkers Prev 2011;20:1350–1357.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Cartwright RA, Watkins G. Epidemiology of Hodgkin's disease: a review. Hematol Oncol 2004;22:11–26.
   PubMed Web of Science ®Google Scholar
• Jarrett AF, Armstrong AA, Alexander E. Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 1996;7(Suppl. 4):5–10.
   PubMed Web of Science ®Google Scholar
• Mack TM, Cozen W, Shibata DK, . Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 1995;332:413–418.
   PubMed Web of Science ®Google Scholar
• Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15–27.
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283–4297.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Massini G, . Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res 2009;33:1352–1356.
   PubMed Web of Science ®Google Scholar
• Rautert R, Schinkothe T, Franklin J, . Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma 2008;49:2091–2098.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Nadali G, Angelopoulou MK, . Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 2001;86:274–281.
   PubMed Web of Science ®Google Scholar
• Monroy CM, Cortes AC, Lopez MS, . Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog 2011;50:36–46.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Di Febo A, . Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007;18:1376–1381.
   PubMed Web of Science ®Google Scholar
• Lan Q, Wang SS, Menashe I, . Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies. Br J Haematol 2011;153:341–350.
   PubMed Web of Science ®Google Scholar
• Cunningham LM, Chapman C, Dunstan R, . Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44: 251–255.
   PubMed Web of Science ®Google Scholar
• Rothman N, Skibola CF, Wang SS, . Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27–38.
   PubMed Web of Science ®Google Scholar
• Fernberg P, Chang ET, Duvefelt K, . Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010;21:759–769.
   PubMed Web of Science ®Google Scholar
• Kube D, Hua TD, von Bonin F, . Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res 2008;14:3777–3784.
   PubMed Web of Science ®Google Scholar
• Lan Q, Zheng T, Rothman N, . Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107:4101–4108.
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Proctor SJ, Taylor PR. Interleukin 4 production by peripheral blood lymphocytes in patients with classical Hodgkin lymphoma. Leuk Res 2004;28:159–166.
   PubMed Web of Science ®Google Scholar
• Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365–386.
   PubMedGoogle Scholar
• Ekstrom PO, Bjorheim J, Gaudernack G, . Population screening of single-nucleotide polymorphisms exemplified by analysis of 8000 alleles. J Biomol Screen 2002;7:501–506.
   PubMed Web of Science ®Google Scholar
• Guldberg P, Gronbak K, Aggerholm A, . Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis. Nucleic Acids Res 1998;26:1548–1549.
   PubMed Web of Science ®Google Scholar
• Watson MA, Stewart RK, Smith GB, . Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998;19:275–280.
   PubMed Web of Science ®Google Scholar
• Harries LW, Stubbins MJ, Forman D, . Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641–644.
   PubMed Web of Science ®Google Scholar
• Matthias C, Bockmuhl U, Jahnke V, . The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics 1998;8:1–6.
   PubMedGoogle Scholar
• Rossi D, Rasi S, Franceschetti S, . Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009;23:1118–1126.
   PubMed Web of Science ®Google Scholar
• Sweeney C, Ambrosone CB, Joseph L, . Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 2003;103:810–814.
   PubMed Web of Science ®Google Scholar
• Sweeney C, McClure GY, Fares MY, . Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000;60:5621–5624.
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998;95:8170–8174.
   PubMed Web of Science ®Google Scholar
• Guy CA, Hoogendoorn B, Smith SK, . Promoter polymorphisms in glutathione-S-transferase genes affect transcription. Pharmacogenetics 2004;14:45–51.
   PubMedGoogle Scholar
• Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994;54:6215–6220.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Nome O, Delabie J, . Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007;48:570–576.
   PubMed Web of Science ®Google Scholar
• Visco C, Vassilakopoulos TP, Kliche KO, . Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma 2004;45:2085–2092.
   PubMed Web of Science ®Google Scholar
• Gibson AW, Edberg JC, Wu J, . Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001;166:3915–3922.
   PubMed Web of Science ®Google Scholar
• Reuss E, Fimmers R, Kruger A, . Differential regulation of interleukin-10 production by genetic and environmental factors--a twin study. Genes Immun 2002;3:407–413.
   PubMed Web of Science ®Google Scholar
• Eskdale J, Gallagher G, Verweij CL, . Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998;95:9465–9470.
   PubMed Web of Science ®Google Scholar
• Eskdale J, Keijsers V, Huizinga T, . Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999;1:151–155.
   PubMed Web of Science ®Google Scholar
• Kurreeman FA, Schonkeren JJ, Heijmans BT, . Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Hum Mol Genet 2004;13:1755–1762.
   PubMed Web of Science ®Google Scholar
• Kilpinen S, Huhtala H, Hurme M. The combination of the interleukin-1alpha (IL-1alpha-889) genotype and the interleukin-10 (IL-10 ATA) haplotype is associated with increased interleukin-10 (IL-10) plasma levels in healthy individuals. Eur Cytokine Netw 2002;13:66–71.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Kawakami K, Kioi M, . Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model. Blood 2005;105:3707–3713.
   PubMed Web of Science ®Google Scholar
• Schoof N, von Bonin F, Zeynalova S, . Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Ann Oncol 2009;20:1548–1554.
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006;112:457–473.
   PubMed Web of Science ®Google Scholar
• Tian C, Ambrosone CB, Darcy KM, . Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2012;124:575–581.
   PubMed Web of Science ®Google Scholar
• Garte S, Gaspari L, Alexandrie AK, . Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239–1248.
   PubMed Web of Science ®Google Scholar
• Sundberg K, Johansson AS, Stenberg G, . Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1 - 1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998;19:433–436.
   PubMed Web of Science ®Google Scholar
• Parl F. A need for true GSTM1 and GSTT1 genotyping. Cancer Epidemiol Biomarkers Prev 2009;18:2793.
   PubMed Web of Science ®Google Scholar
• Edvardsen H, Kristensen VN, Grenaker Alnaes GI, . Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1163–1171.
   PubMed Web of Science ®Google Scholar
• Strange RC, Lear JT, Fryer AA. Glutathione S-transferase polymorphisms: influence on susceptibility to cancer. Chem Biol Interact 1998;111–112:351–364.
   PubMed Web of Science ®Google Scholar
• O’Brien M, Kruh GD, Tew KD. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther 2000;294:480–487.
   PubMed Web of Science ®Google Scholar
• Ban N, Takahashi Y, Takayama T, . Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 1996;56:3577–3582.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733–743.
   PubMed Web of Science ®Google Scholar
• Iyer L, King CD, Whitington PF, . Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847–854.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer 2002;38:639–644.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105–127.
   PubMed Web of Science ®Google Scholar
• Kusama M, Kubota T, Matsukura Y, . Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006;368:93–98.
   PubMed Web of Science ®Google Scholar